Background: Activated-platelet increases the risk of thrombosis in Kawasaki
Thrombin, TXA 2 and ADP are important for platelets activation and coagulation. Aspirin prevents platelet activation via inhibition of TXA 2 production. Clopidogrel is a second-generation ADP receptor antagonist that is usually combined with aspirin for antiplatelet activation. 15 P2RY12 is the target protein of the antiplatelet drug clopidogrel. Clinical studies have shown that KD patients with mild
to moderate coronary artery lesion should take an antiplatelet agent to achieve a better therapeutic effect. 16 P2RY12 gene polymorphisms could affect the pharmacological response to clopidogrel on aggregation. 17 Duan et al. 18 demonstrated that rs1491974 was not associated with coronary heart disease, whereas Timur et al. 19 measured the association of P2RY12 polymorphisms with on-aspirin platelet reactivity and found that rs1491974 showed an association with moderate residual platelet reactivity in coronary artery disease (CAD). Sumitani et al. 20 found that rs9859538 was significantly associated with cancer pain severity. In intracranial artery stenosis patients, rs9859538 was highly expressed in the case group and was associated with an increased likelihood of relapse events. 20 rs9859538 also showed relatively high residual platelet reactivity in CAD. 19 Zee et al. 21 found that rs6809699 could decrease the risk of deep venous thromboembolism/pulmonary embolism in vascular disorders and that P2RY12 rs6809699 could predict bleedings in ST-elevation myocardial infarction patients after percutaneous coronary intervention. 22 rs2046934 was predicted to be a protective factor for clopidogrel resistance in Asian populations. 23 P2RY12 (rs2046934) was identified as being associated with a poor response to clopidogrel treatment in Chinese Han patients with acute coronary syndrome. 24 rs7637803
was associated with low residual platelet reactivity in CAD. 19 One of the most severe complications in KD is CAA, for which a high level of platelet activation is the typical characteristic of KD patients. Aspirin and clopidogrel are normally used in antiplatelet activation in KD patients, especially for complications with CAA.
However, no studies have focused on the connection of the P2RY12 polymorphism with KD genetic susceptibility and CAA complications.
Accordingly, we selected these five single nucleotide polymorphisms (SNPs) in P2RY12 for investigation in the present study.
| MATERIALS AND METHODS
We recruited 776 patients with KD and 1335 healthy controls. The patients were derived from KD cases collected from January 2012
to January 2017 at the Guangzhou Women and Children Medical
Center in China, and 13.27% of the patients had CAA. The KD patients were diagnosed mainly based on the Japanese KD Research Association's comprehensive clinical diagnostic criteria. 25 CAA was diagnosed based on the Japanese Ministry of Health and Welfare criteria for coronary artery abnormalities in children established in 1984 26 : the diameter of the coronary artery before 5 years of age is greater than 3 cm, and it is more than 4 cm after age 5 years. The inner diameter of the coronary artery is 1.5 times that of any adjacent segment. According to the internal diameters of the coronary vessels, patients with CAA were divided into groups: no giant CAA (GCAA-; 
| DNA extraction and genotyping
Samples of 200 μl of anticoagulant-containing blood were collected in accordance with the instructions of the Genomic DNA Extraction Kit (TIANGEN, Beijing, China). The specific procedures have been described previously. 27 The extracted DNA was quantified using a nucleic acid quantifier and stored at −80°C. The P2RY12 polymorphisms were genotyped with TaqMan reagent. Allele-specific probes were purchased from Applied Biosystems (Applied Biosystems, Foster City, CA, USA). The polymerase chain reaction (PCR) was performed in 384-well plates in an ABI-Q6 real-time PCR system. 28 Moreover, to ensure the quality and accuracy of the genotyping results, we randomly selected 10% of the samples for repeat analysis, and the results were found to be 100% concordant.
| Selection of SNPS in the P2RY12 gene
The five selected P2RY12 SNPs that were genotyped were P2RY12:
rs9859538 G>A, P2RY12:rs1491974 G>A, P2RY12:rs7637803 C>T, P2RY12:rs6809699 C>A and P2RY12:rs2046934 A>G.
| Statistical analysis
First, we examined the Hardy-Weinberg equilibrium (HWE) of the samples. Next, a chi-squared test was employed to assess the significance of differences between cases and controls in the frequency distributions and genotypes. The odds ratio (OR) and 95%
confidence interval (CI) were used to quantify the association between each P2RY12 polymorphism and KD susceptibility, with adjustments for age and sex. The associations between the P2RY12 polymorphisms and KD were assessed with stratification by age, sex, CAA and GCAA presence. The statistical analysis procedures have been described previously. 29 3 | RESULTS Table 1 shows the demographic characteristics of KD cases and controls. Mean ± SD age was 29.12 ± 24.68 months (range 1-166 months)
| Demographic characteristics
for KD patients and 23.14 ± 21.72 months (range 1-166 months) for controls. Some 67.53% of KD patients were male, and the male ratio was 65.32% in controls. We further evaluated the effects of the variant genotype polymorphisms on the presence or absence of CAA in KD patients (Table 3) .
Five P2RY12 polymorphism genotypes were used for the analysis.
The result showed that the CT genotype of rs7637803 decreased the risk of CAA in KD patients compared to CC (adjusted OR = 0.41, 
| Stratification analysis
KD is characterized by low age of onset and a high proportion of males. CAA is a severe KD complication, and we found that rs7637803 was associated with CAA risk (Table 3) . Therefore, we ran a stratification analysis on the effects of the P2RY12:rs7637803
C>T polymorphism in cases and controls (Table 4) . We found that rs7637803 was associated with KD risk among the children aged 
| DISCUSSION
The present study investigated the association between KD and five selected P2RY12 polymorphisms. We found no relationship between the five P2RY12 polymorphisms and KD susceptibility. There was also no difference in the proportion of P2RY12 polymorphisms between different gender or age groups. However, single-locus analysis revealed a significant association between the P2RY12:rs7637803
C>T polymorphism in KD cases with and without CAA. This finding indicates that the P2RY12:rs7637803 TT genotype was associated with an increased CAA risk in children aged ≤ 60 months. This polymorphism increased CAA risk in males. The rs7637803 TT genotype rs6787801 was a significant determinant of the interindividual variability in residual on-clopidogrel platelet reactivity in patients with coronary artery disease. Previous research by our group found that the immature platelet fraction can be considered as a risk factor in KD patients. 33 We considered whether there was a relationship between P2RY12 polymorphisms and KD risk. We completed the present study with a large quantity of KD cases, including 776 KD cases and 1335 healthy children from a southern Chinese population. The P2RY12 polymorphism was selected as the study subject. Zhang et al.
22
confirmed that rs6809699 is strikingly associated with bleeding in ST-elevation myocardial infarction patients with percutaneous coronary intervention. However, Li et al. 34 found that rs6809699 had no effect on the ex vivo antiplatelet activity of ticagrelor in healthy Chinese male subjects. We determined that rs6809699 had no effect on KD risk. This result shows that a single genotype can have different functions in different diseases. Most KD children are aged < 5 years. 35 However, the reason why KD more easily occurs in children younger than 5 years still remains unknown. The P2RY12 genotype can influence the age of onset of CAD in smokers. 36 The results of the present study suggest that rs7637803 affects CAA risk in KD patients aged younger than 60 months. The physiological effect of rs7637803 may be one explanation for this association. Timur et al. 19 found that rs1491974 was associated with residual platelet reactivity among CAD patients and the minor alleles of rs1491974 were more likely to have 70% platelet aggregation and result in repeated ischemia.
We did not find a correlation between rs1491974 and KD onset. By contrast, rs7637803 has been associated with residual platelet reactivity and with the effect of clopidogrel as an antiplatelet medication. 19, 20 The present study found that rs7637803 significantly increased the CAA risk in KD patients, although there was no significant association between rs7637803 and KD susceptibility, suggesting that clopidogrel antiplatelet medication has a good effect on KD patients with the rs7637803 genotype. In future studies, we aim to investigate the relationship between clopidogrel and rs7637803 in KD patients.
The present study also has some limitations. We only analyzed a population in southern China; therefore, we lack samples of KD from other parts of China. We ignored the influence of family genetic factors and birth history, as well as the influence of KD patients treated with clopidogrel. Future studies will include these factors to confirm the results obtained in the present study.
